ketanserin has been researched along with Obesity in 4 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Conversely, neither DOI-elicited decreases in food intakes and body weights nor cortical [3H]ketanserin binding were affected by obesity." | 3.69 | Cortical [3H]ketanserin binding and 5-HT2A receptor-mediated behavioral responses in obese Zucker rats. ( Baudrie, V; Chaouloff, F; Coupry, I, 1995) |
| "Current therapeutic treatment for obesity is mostly focused on preventive measures involving dietary control and physical exercises in combination with anti-obesity medications." | 1.39 | Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity. ( Cho, H; Cho, YS; Choi, GD; Choi, K; Im, HY; Jang, H; Kim, CH; Kim, YJ; Ko, M; Kwon, OS; Lee, J; Pae, AN; Park, WK; Seo, YW; Tae, J; Yang, HY, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, HY | 1 |
| Tae, J | 1 |
| Seo, YW | 1 |
| Kim, YJ | 1 |
| Im, HY | 1 |
| Choi, GD | 1 |
| Cho, H | 1 |
| Park, WK | 1 |
| Kwon, OS | 1 |
| Cho, YS | 1 |
| Ko, M | 1 |
| Jang, H | 1 |
| Lee, J | 2 |
| Choi, K | 1 |
| Kim, CH | 1 |
| Pae, AN | 1 |
| Haahr, ME | 1 |
| Hansen, DL | 1 |
| Fisher, PM | 1 |
| Svarer, C | 1 |
| Stenbæk, DS | 1 |
| Madsen, K | 1 |
| Madsen, J | 1 |
| Holst, JJ | 1 |
| Baaré, WF | 1 |
| Hojgaard, L | 1 |
| Almdal, T | 1 |
| Knudsen, GM | 1 |
| Chaouloff, F | 1 |
| Coupry, I | 1 |
| Baudrie, V | 1 |
| Licata, G | 1 |
| Scaglione, R | 1 |
| Parrinello, G | 1 |
| Capuana, G | 1 |
| Mazzola, G | 1 |
| Lipari, R | 1 |
| Galantino, L | 1 |
| Castello, R | 1 |
4 other studies available for ketanserin and Obesity
| Article | Year |
|---|---|
Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Area Under Curve; Azepines; Binding, Competitive; Dose-Response Relati | 2013 |
Central 5-HT neurotransmission modulates weight loss following gastric bypass surgery in obese individuals.
Topics: Adult; Body Mass Index; Brain; Brain Mapping; Case-Control Studies; Denmark; Female; Gastric Bypass; | 2015 |
Cortical [3H]ketanserin binding and 5-HT2A receptor-mediated behavioral responses in obese Zucker rats.
Topics: Amphetamines; Animals; Behavior, Animal; Cerebral Cortex; Down-Regulation; Eating; Ketanserin; Male; | 1995 |
[Clinical and hemodynamic effects of medium-term ketanserin treatment in 2 compared groups of obese and non-obese hypertensive patients].
Topics: Adult; Blood Pressure; Drug Evaluation; Female; Hemodynamics; Humans; Hypertension; Ketanserin; Male | 1989 |